Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Research & Development (2016 - 2025)

Plus Therapeutics has reported Research & Development over the past 15 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Research & Development rose 34.54% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, down 20.8% year-over-year, with the annual reading at $8.4 million for FY2025, 20.8% down from the prior year.
  • Research & Development was $2.9 million for Q4 2025 at Plus Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $3.0 million in Q1 2023 and troughed at $75000.0 in Q4 2023.
  • The 5-year median for Research & Development is $2.2 million (2024), against an average of $2.1 million.
  • Year-over-year, Research & Development plummeted 96.49% in 2023 and then surged 2814.67% in 2024.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then soared by 43.39% to $2.1 million in 2022, then plummeted by 96.49% to $75000.0 in 2023, then surged by 2814.67% to $2.2 million in 2024, then soared by 34.54% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Research & Development are $2.9 million (Q4 2025), $2.4 million (Q3 2025), and $1.2 million (Q2 2025).